WTA
ABMD

Washington Trust Advisors’s Abiomed Inc ABMD Stock Holding History

Washington Trust Advisors’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-470
Closed -$115K – 910
2022
Q3 		$115K Sell
470
-98
-17% -$26.5K 0.01% 258
2022
Q2 		$141K Buy
568
+156
+38% +$42.1K 0.01% 249
2022
Q1 		$136K Buy
+412
New +$127K 0.01% 297

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Washington Trust Advisors's ABMD Position: Q4 2022 in Review

Washington Trust Advisors sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 470 shares — an estimated $115K sold.

Washington Trust Advisors first reported a position in ABMD in Q1 2022 and held it in 3 quarters. The position peaked at $141K in Q2 2022. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Washington Trust Advisors reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Washington Trust Advisors sold 470 Abiomed Inc shares in Q4 2022, an estimated $115K.
  • Washington Trust Advisors first reported a position in Abiomed Inc in Q1 2022 and held it in 3 quarters.
  • Washington Trust Advisors's Abiomed Inc position peaked at $141K in Q2 2022.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Washington Trust Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.